Showing results (61-70 of 131) with videos related to
Sort By:
Pageof 14
Antimicrobial Agents and Chemotherapy|October 3, 1998
Treatment of vancomycin-resistant Enterococcus faecium with RP 59500 (quinupristin-dalfopristin) administered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic infection model with simulated endocardial vegetationsJ R Aeschlimann, M J Zervos, M J RybakAntimicrobial Agents and Chemotherapy|March 18, 2000
In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strainsM J Rybak, E Hershberger, T Moldovan, et al.Antimicrobial Agents and Chemotherapy|February 27, 1999
Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin-sulbactam, trovafloxacin, and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin-intermediate Staphylococcus aureus by time-kill curve methodsE Hershberger, J R Aeschlimann, T Moldovan, et al.Clinical Pharmacology and Therapeutics|May 20, 1998
A dose-response study to assess the renal hemodynamic, vascular, and hormonal effects of eprosartan, an angiotensin II AT1-receptor antagonist, in sodium-replete healthy menB E Ilson, S C Boike, D E Martin, et al.British Journal of Clinical Pharmacology|June 1, 1997
Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin in healthy male volunteersD E Martin, D Tompson, S C Boike, et al.Journal of Clinical Pharmacology|April 1, 1997
Effect of intravenous fenoldopam on intraocular pressure in ocular hypertensionD E Everitt, S C Boike, J R Piltz-Seymour, et al.Journal of Clinical Pharmacology|April 29, 1998
Pharmacokinetics and protein binding of eprosartan in healthy volunteers and in patients with varying degrees of renal impairmentD E Martin, M C Chapelsky, B Ilson, et al.Antimicrobial Agents and Chemotherapy|October 19, 2000
Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection modelJ R Aeschlimann, G P Allen, E Hershberger, et al.Pharmacotherapy|November 11, 1999
Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycosideK R Murry, P S McKinnon, B Mitrzyk, et al.The Journal of Antimicrobial Chemotherapy|April 1, 1988
Comparative efficacies of imipenem-cilastatin and vancomycin in experimental aortic valve endocarditis due to methicillin resistant Staphylococcus aureusP H Chandrasekar, D P Levine, S Price, et al.Pageof 14